Skip to main content

Table 1 4H11-28z/fIL-12/EFGRt T cell dose escalation

From: A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer

Cohort Dose level Cyclophosphamide dose 4H11-28z/fIL-12/EFGRt T cell dose Number of patients
-I −1 None 1 × 105 cells/kg 3-6 patients
I 1 None 3 × 105 cells/kg 3-6 patients
II 1 750 mg/m2 3 × 105 cells/kg 3-6 patients
III 2 750 mg/m2 1 × 106 cells/kg 3-6 patients
IV 3 750 mg/m2 3 × 106 cells/kg 3-6 patients
V 4 750 mg/m2 1 × 107 cells/kg 3-6 patients